Perrigo Gets Positive Judgment In Mucinex Case
Perrigo had been sued by Adams Respiratory Therapeutics, a subsidiary of Reckitt Benckiser Group, the new drug application holder and patent owner. The US District Court for the
The US Food and Drug Administration (FDA) has expanded the approved indication for Bristol Myers Squibb’s (BMS) Camzyos (mavacamten) to treat symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adults and paediatric patients weighing at least 30kg (66lb).